Pharmaceutical sector stocks slipped following reports that the Trump Administration will soon announce tariffs on pharma imports and emphasised that the measures will be ‘unprecedented’.
Aurobindo Pharma is currently trading at Rs. 1112.45, down by 63.60 points or 5.41% from its previous closing of Rs. 1176.05 on the BSE. The scrip opened at Rs. 1175.00 and has touched a high and low of Rs. 1176.60 and Rs. 1049.85 respectively. So far 140673 shares were traded on the counter.
Cipla is currently trading at Rs. 1415.25, down by 79.90 points or 5.34% from its previous closing of Rs. 1495.15 on the BSE. The scrip opened at Rs. 1499.25 and has touched a high and low of Rs. 1499.25 and Rs. 1390.35 respectively. So far 40021 shares were traded on the counter.
Lupin is currently trading at Rs. 1977.75, down by 116.75 points or 5.57% from its previous closing of Rs. 2094.50 on the BSE. The scrip opened at Rs. 2094.35 and has touched a high and low of Rs. 2094.35 and Rs. 1918.20 respectively. So far 51714 shares were traded on the counter.
Sun Pharmaceutical Industries is currently trading at Rs. 1709.00, down by 61.10 points or 3.45% from its previous closing of Rs. 1770.10 on the BSE. The scrip opened at Rs. 1772.10 and has touched a high and low of Rs. 1781.70 and Rs. 1658.00 respectively. So far 88049 shares were traded on the counter.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: